Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress.
暂无分享,去创建一个
S. Steinberg | J. Khan | Jun S. Wei | Y. Pommier | M. Aladjem | V. Rajapakse | B. Elenbaas | J. Trepel | J. Puc | C. Redon | W. Figg | Yilun Sun | M. Ceribelli | C. Peer | Min-Jung Lee | Sam Michael | Craig J. Thomas | Anish Thomas | Sunmin Lee | Erin Beck | Xiaohu Zhang | Lu Chen | A. Zimmermann | Kelli M. Wilson | Z. Itkin | F. Zenke | Christopher W. Schultz | Sehyun Kim | N. Takahashi | A. Yuno | Jessica D Kindrick | Hirity Shimellis | H. Dahmen | Crystal McKnight | Linda Sciuto | Parth Desai | K. Wilson | Yang Zhang | Carleen Klumpp-Thomas | Jameson Travers | Samantha Nichols | Jillian M. Varonin | Akira Yuno
[1] B. Hendriks,et al. Population pharmacokinetics of ATR inhibitor berzosertib in phase I studies for different cancer types , 2020, Cancer Chemotherapy and Pharmacology.
[2] P. Meltzer,et al. SCLC-CellMiner: A Resource for Small Cell Lung Cancer Cell Line Genomics and Pharmacology Based on Genomic Signatures , 2020, Cell reports.
[3] S. Peters,et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. , 2020, The Lancet. Oncology.
[4] D. Pe’er,et al. Lineage plasticity in cancer: a shared pathway of therapeutic resistance , 2020, Nature Reviews Clinical Oncology.
[5] Y. Pommier,et al. BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers , 2020, Science Translational Medicine.
[6] T. Graeber,et al. A genetically defined disease model reveals that urothelial cells can initiate divergent bladder cancer phenotypes , 2019, Proceedings of the National Academy of Sciences.
[7] Damien Y. Duveau,et al. Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening , 2019, Science Translational Medicine.
[8] Aurélie A G Gabriel,et al. Integrative and comparative genomic analyses identify clinically relevant pulmonary carcinoid groups and unveil the supra-carcinoids , 2019, Nature Communications.
[9] M. Lawrence,et al. Combination Olaparib and Temozolomide in Relapsed Small Cell Lung Cancer. , 2019, Cancer discovery.
[10] T. Graeber,et al. Pan-cancer Convergence to a Small-Cell Neuroendocrine Phenotype that Shares Susceptibilities with Hematological Malignancies. , 2019, Cancer cell.
[11] C. Rudin,et al. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data , 2019, Nature Reviews Cancer.
[12] Paul Pinsky,et al. Characteristics and Outcomes of Small Cell Lung Cancer Detected by CT Screening , 2018, Chest.
[13] C. Sander,et al. CellMinerCDB for Integrative Cross-Database Genomics and Pharmacogenomics Analyses of Cancer Cell Lines , 2018, iScience.
[14] A. Mansfield,et al. First‐Line Atezolizumab plus Chemotherapy in Extensive‐Stage Small‐Cell Lung Cancer , 2018, The New England journal of medicine.
[15] Alex H. Wagner,et al. Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer , 2018, Nature Communications.
[16] C. Rudin,et al. Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Y. Pommier,et al. SLFN11 Blocks Stressed Replication Forks Independently of ATR. , 2018, Molecular cell.
[18] J. Minna,et al. Small cell lung cancer tumors and preclinical models display heterogeneity of neuroendocrine phenotypes. , 2018, Translational lung cancer research.
[19] S. Steinberg,et al. Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] N. Socci,et al. Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis , 2017, Clinical Cancer Research.
[21] S. Jackson,et al. ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response. , 2017, Molecular cell.
[22] S. Ramaswamy,et al. ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells , 2017, Genes & development.
[23] M. Rubin,et al. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer , 2017, Science.
[24] Samuel E. Jones,et al. ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A , 2016, Nature Communications.
[25] Panagiotis Kotsantis,et al. Increased global transcription activity as a mechanism of replication stress in cancer , 2016, Nature Communications.
[26] Y. Pommier,et al. Roles of eukaryotic topoisomerases in transcription, replication and genomic stability , 2016, Nature Reviews Molecular Cell Biology.
[27] J. Minna,et al. ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs. , 2016, Cell reports.
[28] Xingming Deng,et al. Targeting DNA Replication Stress for Cancer Therapy , 2016, Genes.
[29] Y. Pommier,et al. Small cell lung cancer: Time to revisit DNA-damaging chemotherapy , 2016, Science Translational Medicine.
[30] Gennady Korotkevich,et al. Fast gene set enrichment analysis , 2016, bioRxiv.
[31] V. Seshan,et al. FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing , 2016, Nucleic acids research.
[32] R. D. de Bruin,et al. Sustained E2F-Dependent Transcription Is a Key Mechanism to Prevent Replication-Stress-Induced DNA Damage , 2016, Cell reports.
[33] P. Pinto,et al. Lack of Impact of Robotic Assisted Laparoscopic Radical Prostatectomy on Intraoperative Levels of Prostate Cancer Circulating Tumor Cells. , 2016, The Journal of urology.
[34] Hongbing Shen,et al. Genomic Landscape Survey Identifies SRSF1 as a Key Oncodriver in Small Cell Lung Cancer , 2016, PLoS genetics.
[35] Matteo Benelli,et al. Divergent clonal evolution of castration resistant neuroendocrine prostate cancer , 2016, Nature Medicine.
[36] N. Horita,et al. Topotecan for Relapsed Small-cell Lung Cancer: Systematic Review and Meta-Analysis of 1347 Patients , 2015, Scientific Reports.
[37] A. Berns,et al. Origins, genetic landscape, and emerging therapies of small cell lung cancer , 2015, Genes & development.
[38] H. Beltran,et al. The spectrum of neuroendocrine tumors: histologic classification, unique features and areas of overlap. , 2015, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
[39] A. Eastman,et al. Will targeting Chk1 have a role in the future of cancer therapy? , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] P. Meltzer,et al. Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. , 2015, The Lancet. Oncology.
[41] Y. Pommier,et al. ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses. , 2014, Cancer research.
[42] I. Drozdov,et al. Gene network-based analysis identifies two potential subtypes of small intestinal neuroendocrine tumors , 2014, BMC Genomics.
[43] J. Diffley,et al. DNA Replication and Oncogene-Induced Replicative Stress , 2014, Current Biology.
[44] David Hsu,et al. OpenComet: An automated tool for comet assay image analysis , 2014, Redox biology.
[45] K. Cimprich,et al. Causes and consequences of replication stress , 2013, Nature Cell Biology.
[46] L. Zou,et al. Two distinct modes of ATR activation orchestrated by Rad17 and Nbs1. , 2013, Cell reports.
[47] Takanori Fujita,et al. PRC2 overexpression and PRC2-target gene repression relating to poorer prognosis in small cell lung cancer , 2013, Scientific Reports.
[48] Justin Guinney,et al. GSVA: gene set variation analysis for microarray and RNA-Seq data , 2013, BMC Bioinformatics.
[49] Robert Gentleman,et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer , 2012, Nature Genetics.
[50] Martin A. M. Reijns,et al. Enzymatic Removal of Ribonucleotides from DNA Is Essential for Mammalian Genome Integrity and Development , 2012, Cell.
[51] M. Barbacid,et al. Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors , 2011, Nature Structural &Molecular Biology.
[52] James R Bischoff,et al. A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations , 2011, Nature Structural &Molecular Biology.
[53] Helga Thorvaldsdóttir,et al. Molecular signatures database (MSigDB) 3.0 , 2011, Bioinform..
[54] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[55] H. Hakonarson,et al. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data , 2010, Nucleic acids research.
[56] Richard Durbin,et al. Fast and accurate long-read alignment with Burrows–Wheeler transform , 2010, Bioinform..
[57] Davis J. McCarthy,et al. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..
[58] J. D. Vos,et al. Topoisomerase I suppresses genomic instability by preventing interference between replication and transcription , 2009, Nature Cell Biology.
[59] Jiri Bartek,et al. An Oncogene-Induced DNA Damage Model for Cancer Development , 2008, Science.
[60] Y. Pommier,et al. The Intra-S-Phase Checkpoint Affects both DNA Replication Initiation and Elongation: Single-Cell and -DNA Fiber Analyses , 2007, Molecular and Cellular Biology.
[61] T. Ciuleanu,et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[62] Dimitris Kletsas,et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints , 2006, Nature.
[63] Wolf-Dietrich Heyer,et al. Rad54: the Swiss Army knife of homologous recombination? , 2006, Nucleic acids research.
[64] N. Hanna,et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[65] T. Ørntoft,et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis , 2005, Nature.
[66] Dimitris Kletsas,et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions , 2005, Nature.
[67] A. Kumagai,et al. Claspin, a novel protein required for the activation of Chk1 during a DNA replication checkpoint response in Xenopus egg extracts. , 2000, Molecular cell.
[68] K. Kohn,et al. Replication‐mediated DNA damage by camptothecin induces phosphorylation of RPA by DNA‐dependent protein kinase and dissociates RPA:DNA‐PK complexes , 1999, The EMBO journal.
[69] J. Carmichael,et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[70] M. Prichard,et al. A three-dimensional model to analyze drug-drug interactions. , 1990, Antiviral research.
[71] J. Minna,et al. Characterization of variant subclasses of cell lines derived from small cell lung cancer having distinctive biochemical, morphological, and growth properties. , 1985, Cancer research.
[72] J. Bishop,et al. INSM1 is a Sensitive and Specific Marker of Neuroendocrine Differentiation in Head and Neck Tumors , 2018, The American journal of surgical pathology.
[73] Yilun Sun,et al. Detection of Topoisomerase Covalent Complexes in Eukaryotic Cells. , 2018, Methods in molecular biology.
[74] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.